Product News

Share this article:
The FDA has granted Caraco Pharmaceutical Laboratories approval for its Abbreviated New Drug Application (ANDA) for Phentermine Hydrochloride Tablets indicated as short-term monotherapy for the management of exogenous obesity. According to IMS data, for the 12 months ended June 2007, Phentermine HCl generic and brand products (Adipex-P) combined had annual sales of approximately $34 million.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions